Clinical trial · Interventional
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
NCT00156884CI-TRIAL-00006082completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
| Hormone Refractory Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| strontium-89 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Palliative pain response
- measure
- analgesic response
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * adenocarcinoma of the prostate * life expectancy \> 3 months, * symptomatic from bone metastases * radiologic evidence of metastatic bone disease * stable level of pain control * \>18 years * ability to complete assessments * prior treatment (chemo) \> 4 weeks previous * discontinued anti-androgens for \> 4 weeks Exclusion Criteria: * prior strontium therapy * previous hemibody RT within 6 weeks * previous cytotoxic chemotherapy within 4 weeks * use of bisphosphonate medications within 4 weeks * change in steroid dose within 4 weeks * active uncontrolled infection * impending or present spinal cord compression * significant neurological disorder * impending pathological fracture * severe urinary incontinence
References
Publications (0)
Data not yet available
No reference posted for this study.